NWF Advisory Services Inc. acquired a new stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the 2nd quarter, HoldingsChannel reports. The firm acquired 10,426 shares of the exchange traded fund’s stock, valued at approximately $1,650,000.
Other hedge funds also recently added to or reduced their stakes in the company. Compound Planning Inc. grew its stake in shares of SPDR S&P Biotech ETF by 0.7% in the 1st quarter. Compound Planning Inc. now owns 10,889 shares of the exchange traded fund’s stock valued at $1,391,000 after purchasing an additional 75 shares during the last quarter. Dynamic Wealth Strategies LLC raised its stake in shares of SPDR S&P Biotech ETF by 3.8% during the fourth quarter. Dynamic Wealth Strategies LLC now owns 2,201 shares of the exchange traded fund’s stock worth $268,000 after purchasing an additional 80 shares during the last quarter. PeakShares LLC raised its stake in shares of SPDR S&P Biotech ETF by 5.2% during the first quarter. PeakShares LLC now owns 1,684 shares of the exchange traded fund’s stock worth $215,000 after purchasing an additional 84 shares during the last quarter. Commerce Bank lifted its holdings in shares of SPDR S&P Biotech ETF by 2.8% during the fourth quarter. Commerce Bank now owns 3,260 shares of the exchange traded fund’s stock worth $397,000 after purchasing an additional 90 shares during the period. Finally, Moors & Cabot Inc. lifted its holdings in shares of SPDR S&P Biotech ETF by 3.8% during the third quarter. Moors & Cabot Inc. now owns 2,717 shares of the exchange traded fund’s stock worth $272,000 after purchasing an additional 100 shares during the period.
SPDR S&P Biotech ETF Price Performance
NYSEARCA:XBI opened at $164.38 on Friday. The firm has a market cap of $10.73 billion, a price-to-earnings ratio of 11.47 and a beta of 0.84. The firm’s fifty day moving average price is $158.01 and its 200 day moving average price is $140.34. SPDR S&P Biotech ETF has a 1-year low of $92.49 and a 1-year high of $169.89.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Recommended Stories
- Five stocks we like better than SPDR S&P Biotech ETF
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
